Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-Trastuzumab

Jason P. Holland; Eloisi Caldas-Lopes; Vadim Divilov; Valerie A. Longo; Tony Taldone; Danuta Zatorska; Gabriela Chiosis; Jason S. Lewis

doi:10.1371/journal.pone.0008859

Loading metrics

Open Access

Peer-reviewed

Research Article

Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using ⁸⁹Zr-DFO-Trastuzumab

Jason P. Holland,

Affiliation Radiochemistry Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Eloisi Caldas-Lopes,

Affiliation Program in Molecular Pharmacology and Chemistry, Sloan Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Vadim Divilov,

Affiliation Radiochemistry Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Valerie A. Longo,

Affiliation Small-Animal Imaging Core Facility, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Tony Taldone,

Affiliation Program in Molecular Pharmacology and Chemistry, Sloan Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Danuta Zatorska,

Affiliation Program in Molecular Pharmacology and Chemistry, Sloan Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Gabriela Chiosis,

Affiliation Program in Molecular Pharmacology and Chemistry, Sloan Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Jason S. Lewis

* E-mail: lewisj2@mskcc.org

Affiliations Radiochemistry Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Cancer Center, New York, New York, United States of America, Program in Molecular Pharmacology and Chemistry, Sloan Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯

Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using ⁸⁹Zr-DFO-Trastuzumab

Jason P. Holland,
Eloisi Caldas-Lopes,
Vadim Divilov,
Valerie A. Longo,
Tony Taldone,
Danuta Zatorska,
Gabriela Chiosis,
Jason S. Lewis

Published: January 25, 2010
https://doi.org/10.1371/journal.pone.0008859

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Lung and intrathoracic tumors
Is the Subject Area "Lung and intrathoracic tumors" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Pharmacodynamics
Is the Subject Area "Pharmacodynamics" applicable to this article?

Thanks for your feedback.
Radiolabeling
Is the Subject Area "Radiolabeling" applicable to this article?

Thanks for your feedback.
Positron emission tomography
Is the Subject Area "Positron emission tomography" applicable to this article?

Thanks for your feedback.
Radionuclide imaging
Is the Subject Area "Radionuclide imaging" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.